Welcome to my minihompy! β¨
Loading Reality...
No comments yet. Be the first to say something!
π Part of the TILA-278 Regulatory Dossier β Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing β the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Region-specific administrative document for the TILA-278 marketing application.
Why it exists. Region-specific administrative content the agency requires in front of the scientific dossier.
How it is produced here. This is a region-specific administrative document, assembled to the local filing and labeling conventions. Its operational and label content is written to stay consistent with the (simulated) clinical data.
Format & governing standard. ICH M4 / regional
| Field | Value |
|---|---|
| Document ID | M1-0 |
| Version | 1.0 |
| Compound | TILA-278 (anti-TL1A antagonist / IL-22R agonist bispecific) |
| Standard | ICH M4 / regional |
| Confidentiality | Confidential |
Region-specific administrative document for the TILA-278 marketing application.
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-07-08 | Regulatory Affairs | Initial issue |
This index constitutes the Module 1 (M1) administrative layer of the Common Technical Document (CTD) for TILA-278 (Virtual Biopharma Inc.). Module 1 is the region-specific "cover" of the dossier: unlike the harmonized scientific Modules 2β5 (ICH M4), Module 1 content, numbering, and format are defined independently by each regulatory authority. This section lists, and briefly describes the content and status of, every M1 component filed in front of the TILA-278 scientific dossier for the U.S. FDA, the EU EMA, and the Korean MFDS, and maps each administrative form, certification, and cross-reference to its regional location.
TILA-278 is a recombinant humanized IgG1 bispecific monoclonal antibody in which one arm antagonizes TL1A (TNFSF15) and the other acts as an interleukin-22 receptor (IL-22R) agonist. It is administered subcutaneously (SC) as a single-use prefilled syringe and autoinjector for the treatment of moderate-to-severe active ulcerative colitis (UC). The application is supported by the pivotal Phase 2b induction study TILA278-201.
Table 1.1 β Product and application identifiers
| Attribute | Value |
|---|---|
| Proprietary / product name | TILA-278 |
| Sponsor / Applicant / Marketing Authorisation Holder (MAH) | Virtual Biopharma Inc. |
| Substance class | Recombinant humanized IgG1 bispecific monoclonal antibody (anti-TL1A Γ IL-22R agonist) |
| Pharmaceutical form / route | Solution for injection in a single-use prefilled syringe and autoinjector; subcutaneous |
| Proposed indication | Induction of clinical remission in adults with moderate-to-severe active ulcerative colitis |
| Pivotal study | TILA278-201 (Phase 2b, randomized, double-blind, placebo-controlled, 12-week induction) |
| U.S. application type | Biologics License Application (BLA), PHS Act Β§351(a); IND (to be assigned) |
| EU application type | Centralised Marketing Authorisation Application (MAA), full/complete application (Art. 8(3), Directive 2001/83/EC) |
| Korea application type | Item import licence (μμ νλͺ©νκ°), biological product / recombinant new drug (μ μ½) |
Because Module 1 is not harmonized, three parallel, self-contained M1 assemblies are maintained, each governed by the applicable regional eCTD specification and administrative guidance:
The pivotal efficacy and safety dataset referenced throughout the M1 labeling, risk-management, and clinical-trial components is Study TILA278-201: 1,700 screened and 900 randomized 1:1:1 to TILA-278 High (299), TILA-278 Low (300), and Placebo (301), stratified by baseline modified Mayo severity and prior biologic exposure. The primary endpoint β clinical remission (modified Mayo β€2, with no individual subscore >1) at Week 12 β was met, with dose-ordered remission of 37.3% / 16.2% / 0.7% (High/Low/Placebo) and both active arms superior to placebo (p<0.0001). The key continuous measure, LS-mean change from baseline in modified Mayo at Week 12, was β3.36 / β2.76 / β1.00, a difference versus placebo of β2.36 (95% CI β2.49, β2.23) for High and β1.77 (95% CI β1.90, β1.64) for Low (p<0.0001 for both). These figures are carried consistently into the Annex I / Prescribing Information / 첨λΆλ¬Έμ clinical-particulars text and into the regional risk-management documents.
Table 2.1 β TILA278-201 pivotal dataset carried into regional labeling and risk-management text
| Parameter | TILA-278 High | TILA-278 Low | Placebo |
|---|---|---|---|
| Randomized, N | 299 | 300 | 301 |
| Clinical remission at Week 12 (primary), n/N (%) | 106/284 (37.3%) | 46/283 (16.2%) | 2/273 (0.7%) |
| Modified Mayo, LS-mean change from baseline at Week 12 | β3.36 | β2.76 | β1.00 |
| Difference vs placebo (95% CI) | β2.36 (β2.49, β2.23) | β1.77 (β1.90, β1.64) | β |
| p-value vs placebo | <0.0001 | <0.0001 | β |
| Subjects with β₯1 TEAE, n | 109 | 131 | 130 |
| Serious adverse events, n | 3 | 0 | 4 |
| Deaths (all assessed as unrelated), n | 2 | 0 | 1 |
| Discontinuations, n | 17 | 17 | 29 |
Efficacy is presented for the full analysis set (ANCOVA); the primary endpoint is Week-12 clinical remission. Safety counts are from treated subjects. Discontinuations on placebo were driven predominantly by lack of efficacy.
The U.S. Module 1 assembles the BLA forms, certifications, labeling, and administrative correspondence in front of Modules 2β5. Each heading below reflects the FDA eCTD Module 1 hierarchy.
Table 3.1 β FDA Module 1 index
| M1 heading | Component | Description / TILA-278 content | Status |
|---|---|---|---|
| 1.1 | Forms | Form FDA 356h (Application to Market a New or Abbreviated New Drug, Biologic, or Antibiotic Drug for Human Use) as the BLA cover form; Form FDA 3397 (User Fee Cover Sheet); Form FDA 3674 (ClinicalTrials.gov certification). | Final |
| 1.2 | Cover letter | Signed cover letter identifying submission type (original BLA), review division (Gastroenterology), contents, and any designation references. | Final |
| 1.3.1 | Applicant / contact and agent information | U.S. agent, authorized official, and regulatory contact for Virtual Biopharma Inc. | Final |
| 1.3.2 | Field copy certification | Certification per Form FDA 356h regarding the field copy, addressed in accordance with current eCTD practice. | Final |
| 1.3.3 | Debarment certification | Certification under Section 306(k)(1) of the FD&C Act that no debarred person was used in preparing or developing the BLA. | Final |
| 1.3.4 | Financial certification and disclosure | Investigator financial-disclosure package for TILA278-201: Form FDA 3454 (certification of no disclosable interests) and, where applicable, Form FDA 3455 (disclosure of interests/arrangements). | Final |
| 1.3.5 | Patent and exclusivity information | Statement that Orange Book patent listing/certification does not apply to a Β§351(a) biologic; any patent exchange proceeds under the BPCIA "patent dance" outside the BLA. | Final |
| 1.4 | References (letters of authorization, cross-references) | Letters of authorization to cross-reference the drug-substance (CHO cell line / master cell bank) and device (prefilled syringe / autoinjector) master files β Drug Master File(s) and device Master Access File(s) (to be assigned). | Final |
| 1.5 | Application status | Original submission; not a resubmission. | Final |
| 1.6 | Meetings | Minutes and correspondence for pre-IND, End-of-Phase-2, and pre-BLA meetings (to be assigned). | Final |
| 1.7 | Designations (Fast Track / Breakthrough) | Reference to Breakthrough Therapy / Fast Track designation request and grant, as applicable (to be assigned). | Final |
| 1.9 | Pediatric administrative information | Initial Pediatric Study Plan (iPSP) and PREA assessment for pediatric UC, with proposed deferral of post-approval studies and a partial waiver below the youngest feasible age (to be assigned). |
Certifications of note (US). Three certifications form the compliance backbone of the U.S. Module 1: the debarment certification (Section 306(k)(1) of the FD&C Act), the financial certification and disclosure package for all TILA278-201 clinical investigators (Forms FDA 3454/3455 under 21 CFR Part 54), and the ClinicalTrials.gov certification (Form FDA 3674) attesting to compliance with 42 U.S.C. Β§282(j) registration and results-reporting for the pivotal trial. The PDUFA program fee obligation is documented on Form FDA 3397 (to be assigned).
Patent handling (US). As a biologic licensed under Β§351(a), TILA-278 is not subject to Orange Book patent listing or Paragraph IβIV certifications; the patent-information field is addressed by an explanatory statement, with any patent disputes governed by the Biologics Price Competition and Innovation Act (BPCIA).
Labeling (US). The Prescribing Information conforms to the PLR/PLLR content and format requirements, including the Highlights, the Pregnancy and Lactation subsections, and device-specific Instructions for Use for both the prefilled syringe and the autoinjector presentations.
The EU Module 1 is built for the centralised procedure and is dominated by the electronic Application Form (eAF), the full product-information Annexes, the expert declarations, and the pharmacovigilance / RMP package.
Table 4.1 β EMA Module 1 index
| M1 heading | Component | Description / TILA-278 content | Status |
|---|---|---|---|
| 1.0 | Cover letter | Cover letter confirming centralised eligibility (biotechnology / recombinant), legal basis (Art. 8(3)), and, if granted, accelerated-assessment / PRIME references. | Final |
| 1.1 | Comprehensive table of contents | EU-wide table of contents across Modules 1β5. | Final |
| 1.2 | Application form (eAF) | Completed EU electronic Application Form: applicant (Virtual Biopharma Inc.), invented name, ATC code, legal basis, manufacturing sites (CHO drug substance and drug-product fill/finish), and proposed indication. | Final |
| 1.3.1 | Product information (SmPC, labelling, package leaflet) | Annex I (SmPC), Annex IIIA (labelling), Annex IIIB (package leaflet). SmPC Section 5.1 presents TILA278-201 efficacy (LS-mean change in modified Mayo at Week 12: High β3.36 / Low β2.76 / Placebo β1.00; Week-12 remission 37.3% / 16.2% / 0.7%). | Final (proposed) |
| 1.3.2β1.3.3 | Mock-ups and specimens | Mock-ups and specimens of outer and immediate packaging for the prefilled syringe and autoinjector presentations. | Final |
| 1.3.4 | Consultation with target patient groups | Package-leaflet readability (user) testing report and bridging rationale. | Final |
| 1.3.6 | Braille | Braille statement for outer packaging (product name and strength). | Final |
| 1.4.1β1.4.3 | Expert declarations | Quality, non-clinical, and clinical expert statements with signatures and CVs. | Final |
| 1.5 | Specific requirements | Requests and decisions on accelerated assessment, conditional marketing authorisation, and PRIME eligibility, as applicable (to be assigned). | Final |
| 1.6.1 | Environmental Risk Assessment (ERA) | ERA justification that TILA-278, a protein / monoclonal antibody, is expected to be metabolised to endogenous peptides and amino acids and to pose a negligible environmental risk (per EMA guidance); GMO provisions are not applicable. | Final |
| 1.7 | Orphan-market-exclusivity information | Not applicable β moderate-to-severe UC is not an orphan indication. | N/A |
| 1.8.1 | Pharmacovigilance system | Summary of the applicant's pharmacovigilance system, with reference to the Pharmacovigilance System Master File (PSMF) (to be assigned) and the QPPV. | Final |
| 1.8.2 | Risk Management Plan (EU-RMP) | EU-RMP (GVP Module V) with safety specification, pharmacovigilance plan, and risk-minimisation measures. Injection-site reactions and immunogenicity are managed as routine; no additional risk-minimisation measures are proposed on the basis of the TILA278-201 profile. |
Product information (EU). The three legally binding Annexes (SmPC, labelling, package leaflet) are the centrepiece of the EU Module 1. The SmPC clinical sections reproduce the pivotal TILA278-201 outcomes in the harmonized EU wording, and the dual mechanism β TL1A antagonism (dampening TH1/TH17 inflammation and intestinal fibrosis) together with IL-22R agonism (driving epithelial regeneration and mucosal-barrier repair) β is summarised in Section 5.1.
Pharmacovigilance and RMP (EU). The EU-RMP is cross-referenced from Module 1 but drives content in Modules 2.5/2.7 and Module 5. Its safety specification comprises: an important identified risk of injection-site reactions; important potential risks of immunogenicity (anti-drug antibodies, with potential impact on pharmacokinetics, efficacy, and safety) and of serious or opportunistic infection consistent with an immunomodulatory mechanism; a theoretical consideration of epithelial-proliferative effects attributable to IL-22R agonism, to be characterised through routine pharmacovigilance and confirmatory studies; and missing information covering long-term safety beyond the 12-week induction period, use in pregnancy and lactation, and use in special populations. Given the absence of a dose-dependent safety signal in TILA278-201, routine pharmacovigilance and routine risk-minimisation (product information) are proposed as sufficient.
The Korean Module 1 follows the MFDS CTD structure for a biological (recombinant) new-drug import licence and emphasizes the Korean-language application form and labeling, overseas GMP evidence, patent-list registration, the RMP, and the re-examination designation.
Table 5.1 β MFDS Module 1 index
| M1 heading | Component | Description / TILA-278 content | Status |
|---|---|---|---|
| 1.1 | λͺ©μ°¨ (Table of contents) | Korea-specific comprehensive table of contents. | Final |
| 1.2 | μ μ²μ (Application form) | Item import-licence application (μμ νλͺ©νκ° μ μ²μ) identifying Virtual Biopharma Inc., the recombinant biological classification, the presentations (prefilled syringe / autoinjector), and the proposed indication. | Final |
| 1.3 | μ νμ 보 / 첨λΆλ¬Έμ (Product information / labeling) | Korean prescribing information (첨λΆλ¬Έμ / νκ°μ¬ν), container and carton labeling (μ©κΈ°Β·ν¬μ₯ νμ), and Korean precautions for use (μ¬μ©μμ μ£Όμμ¬ν). The clinical-particulars text reflects TILA278-201 Week-12 remission and modified-Mayo results. | Final (proposed) |
| 1.4 | κ΅λ΄Β·μΈ νκ° νν© (Domestic / foreign approval status) | Status of the corresponding BLA/MAA and any reference-country approvals; certificates of pharmaceutical product (CPP) as available (to be assigned). | Final |
| 1.5 | GMP κ΄λ ¨ μλ£ (GMP documentation) | Overseas manufacturing-site GMP assessment materials for the CHO drug-substance and drug-product fill/finish sites (ν΄μΈμ μ‘°μ GMP νκ°). | Final |
| 1.6 | νΉν κ΄λ ¨ μλ£ (Patent information) | Drug patent-linkage patent-list registration (μμ½ν νΉνλͺ©λ‘ λ±μ¬) information. | Final |
| 1.7 | μν΄μ± κ΄λ¦¬ κ³ν (RMP) | MFDS Risk Management Plan per the Korean RMP guideline, aligned with the EU-RMP safety specification (injection-site reactions; immunogenicity; infection; long-term safety as missing information). | Final |
| 1.8 | μ¬μ¬μ¬ (Re-examination / PMS) | New-drug re-examination designation and post-marketing surveillance plan (μ μ½ μ¬μ¬μ¬; new active ingredients are typically designated for a 6-year period). | Final |
| μλ£μμ½ν λ±λ‘ (referenced) | Drug Master File (DMF) reference | Cross-reference to the registered drug-substance master file for the recombinant antibody, where applicable (to be assigned). | Final |
Notes (Korea). As a recombinant biological new drug manufactured outside Korea, the application is an import item licence supported by overseas GMP assessment; the product is designated for post-marketing re-examination, and an MFDS RMP is mandatory. Korean labeling (νκΈ νμκΈ°μ¬) and the 첨λΆλ¬Έμ must carry the approved particulars, including the SC device Instructions for Use.
Table 6.1 β Where each administrative element lives, by region
| Administrative element | FDA (US) | EMA (EU) | MFDS (Korea) |
|---|---|---|---|
| Primary application form | Form FDA 356h (M1.1) | eAF (M1.2) | μμ νλͺ©νκ° μ μ²μ (M1.2) |
| User / registration fee | Form FDA 3397 (M1.1) | Centralised procedure fee (per EMA fee rules) | MFDS review fee |
| Financial-disclosure certification | Forms FDA 3454/3455 (M1.3.4) | Covered within GCP / trial info (M1.9) | Within study / GCP documentation |
| Debarment / integrity certification | Β§306(k)(1) certification (M1.3.3) | No direct equivalent; GMP/GCP declarations | Covered by GMP/GCP evidence |
| Clinical-trials registration certification | Form FDA 3674 (M1.1) | Clinical-trials info (M1.9) | Within study documentation |
| Patent information | BPCIA statement; Orange Book N/A (M1.3.5) | Not part of the MA dossier | Patent-list registration (M1.6) |
| Prescribing information / labeling | PI + Medication Guide + IFU (M1.14) | SmPC / labelling / PL Annexes (M1.3) | 첨λΆλ¬Έμ / νμ (M1.3) |
| Risk management | REMS assessment (M1.16) | EU-RMP (M1.8.2) | MFDS RMP (M1.7) |
| Pediatric plan | iPSP / PREA (M1.9) | PIP (M1.10) | Addressed via re-examination / labeling |
| Environmental risk | Addressed in the scientific modules | ERA (M1.6.1) | Addressed as applicable |
| GMP of active-substance manufacturer | LOA to master files (M1.4) | QP declaration (3.2.R, referenced) | ν΄μΈμ μ‘°μ GMP μλ£ (M1.5) |
Module 1 is administrative but repeatedly references the scientific dossier; the following linkages are maintained so that reviewers can trace each M1 commitment to its underlying data:
All region-specific Module 1 assemblies are compiled to their respective valid eCTD backbones. Forms, certifications, labeling, and risk-management documents are final at submission; promotional materials (US M1.15) are deferred to launch. Administrative identifiers marked (application/IND/BLA numbers, EU CT/CTIS numbers, PIP/iPSP references, PSMF and master-file numbers, fee amounts, meeting IDs, and dates) correspond to authority-assigned values that are populated at the time of filing and reconciled across the three regional dossiers, so that the underlying TILA-278 (Virtual Biopharma Inc.) program and the TILA278-201 pivotal dataset remain consistent across regions.
| Final |
| 1.12 | Other correspondence | General administrative correspondence and Type C / advice-letter exchanges. | Final |
| 1.14.1 | Draft labeling | Prescribing Information in Physician Labeling Rule (PLR) / PLLR format, Medication Guide / patient labeling, and Instructions for Use for the SC prefilled syringe and autoinjector. The Clinical Studies section reflects TILA278-201 Week-12 remission and modified-Mayo results. | Final (proposed labeling) |
| 1.14.3 | Listing of labeling | Structured Product Labeling (SPL) and container / carton labeling for the single-use device presentations. | Final |
| 1.15 | Promotional material | Launch promotional materials, submitted at or after approval as applicable. | Not yet applicable |
| 1.16 | Risk management / REMS | REMS assessment. Given the TILA278-201 safety profile (no dose-dependent safety signal; injection-site reactions the principal drug-attributable finding; SAEs 3/0/4 and deaths 2/0/1, all assessed as unrelated), a REMS is proposed as not warranted, and routine labeling-based risk management is proposed. | Final |
| 1.20 | General investigational plan | Historical; carried from the IND. | Final |
| Final |
| 1.9 | Information relating to clinical trials | GCP compliance statement and list of clinical trials, including TILA278-201 (to be assigned), with confirmation of ethics-committee and competent-authority oversight. | Final |
| 1.10 | Information relating to paediatrics | Paediatric Investigation Plan (PIP) decision and compliance statement, with agreed deferrals and any age-based waiver for paediatric UC (to be assigned). | Final |
| 3.2.R (referenced in M1) | QP declaration on active-substance GMP | Qualified-Person declaration(s) on the GMP compliance of the CHO drug-substance manufacturer(s), located in Module 3.2.R and cross-referenced from Module 1. | Final |